ARA-290 (Cibinetide): A Tracking Guide for Tissue Protection and Neuropathic Pain

ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from helix B of erythropoietin. It was designed to activate the tissue-protective EPO receptor complex without driving red blood cell production. Most of the human data is in small-fiber neuropathy, including small trials in sarcoidosis and diabetic neuropathy. It is not approved by major regulators.

What it is supposed to do

The intended action is on a heteromeric receptor formed by EPOR and the beta common receptor, which signals tissue protection and anti-inflammatory effects rather than erythropoiesis. In published trials, ARA-290 has been associated with improvements in patient-reported neuropathic symptoms and some measures of small nerve fiber function.

Typical protocol shape

• Route: subcutaneous injection
• Frequency: once daily
• Dose: trial doses were commonly 4 mg/day; self-reports cluster in a similar range
• Duration: 4–12 week blocks; published trials ran around 28 days

Because of its specific neuropathy positioning, this peptide is most often used by people with a defined symptom they are trying to influence, not as a general wellness compound.

What to track daily

• Pain rating (0–10), morning and evening
• Burning, tingling, or numbness location and intensity
• Sleep quality and any pain-related wake-ups
• Mood and energy
• Injection site reactions

What to track weekly

• A standardized neuropathic symptom score, such as the SFN-SIQ if your symptoms fit
• Functional metrics: standing time, walking distance, fine motor tasks
• Medication use (analgesics, gabapentin, etc.)
• Sleep summary

Bloodwork worth doing

• Baseline and end-of-cycle CBC, specifically hematocrit and hemoglobin, to confirm the "no erythropoiesis" property in your own data
• Inflammatory markers like hs-CRP
• HbA1c if neuropathy is diabetes-related
• B12 and folate, since deficiencies confound neuropathy interpretation

Realistic expectations

In published work, effects are modest and most visible in patient-reported outcomes rather than objective nerve conduction. Some people describe meaningful reductions in burning pain and improvements in sleep, while others see nothing. A clean, structured 4–8 week trial with daily symptom logging in Peptide IA is the only way to know which group you are in.

Common mistakes

• Starting ARA-290 at the same time as a new analgesic or nerve-pain medication
• Tracking only "did it help" instead of a numeric pain score
• Using it as a general anti-inflammatory without a defined symptom to measure
• Skipping baseline CBC, then having no way to evaluate safety claims

A tracking template

• Week 0: baseline bloodwork, baseline symptom questionnaire, two weeks of daily pain scores
• Weeks 1–4: daily injections, daily symptom log
• Week 4: repeat symptom questionnaire and bloodwork
• Weeks 5–8: optional extension if you saw a partial response
• Weeks 9–12: washout; track whether symptoms return, and over what timeframe

Bottom line

ARA-290 has one of the more coherent mechanistic and clinical stories among research peptides, but the trials are small and it is not approved. It is best used with a specific, measurable symptom and a structured tracking plan. If your pain scores do not move over a clean four-week block, the honest read is non-response, not "needs more time."

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.